A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Objective: The objective of this study is to evaluate efficacy and safety of SPN-812 (extended-release viloxazine) for ADHD in children aged 6 to 12 years. Method: In an 8-week study, 222 participants were randomized to placebo or SPN-812 100, 200, 300, or 400 mg/day. Measurements included ADHD Rating Scale (RS)-IV total score and Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety assessments included laboratory and electrocardiogram (ECG) measurements, suicidality monitoring (Columbia-Suicide Severity Rating Scale), and adverse event (AE) reporting. Results: Significant improvements in ADHD-RS-IV total score were observed for 200, 300, and 400 mg dose groups versus placebo ( p < .05; effect size [ES] = 0.547, 0.596, and 0.623). CGI-I score for the 300 mg group and CGI-S score for all SPN-812 groups except for 100 mg improved significantly ( p < .05) versus placebo. The most frequent AEs (≥15%) were somnolence, headache, and decreased appetite. Conclusion: SPN-812 significantly reduced the severity of ADHD symptoms and was well tolerated. The efficacy and safety of SPN-812 are being investigated in Phase III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the side effects of viloxazine such as somnolence are a possible impediment to its utility in CDS treatment [76]”
From Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research (2023) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
(1976) · Medical Entomology and Zoology · Cited by 8,899
The clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed Central · Cited by 2,806
Diagnostic and Statistical Manual of Mental Disorders
Raber, G., & Spokas, M. (2025) · The Sage Encyclopedia of Mood and Anxiety Disorders · doi:10.4135/9781071886229.n145 · Cited by 2,764
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Sheehan, D. V., Sheehan, K. H., Shytle, R. D., Janavs, J., Bannon, Y., Rogers, J. E., Milo, K. M., Stock, S. L., & Wilkinson, B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05305whi · Cited by 1,730
Danielson, M. L., Bitsko, R. H., Ghandour, R. M., Holbrook, J. R., Kogan, M. D., & Blumberg, S. J. (2018) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2017.1417860 · Cited by 1,181 · cited 2×
“4% of that population) having received an ADHD diagnosis in 2016 (Adesman, 2001; Danielson et al., 2018).”
BackgroundInfluentialNeuropsychiatric Disease and Treatment
Tóth-Czifra, E. (2017) · doi:10.14293/s2199-1006.1.sor-med.clwxpbd.v1 · Cited by 929
Harpin, V. A. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2004.059006 · Cited by 789
The quality of life of children with attention deficit/hyperactivity disorder: a systematic review
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., Santosh, P., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0046-3 · Cited by 516 · cited 1×
“Children experiencing symptoms of ADHD may have difficulties in the school setting that limit academic achievement; the symptoms may also affect the quality of life of these children and their families (Danckaerts et al., 2010; Harpin, 2005; Peasgood et al., 2016).”
Background
Research works printed but not linked: 3
- Johnson J. K. Saylor K. Brittain S. T. Tulloch G. Liranso T. (2015, 10 26-31). Double-blind, randomized, placebo-controlled study of immediate-release viloxazine (SPN-812 IR) as a novel non-stimulant therapy in adults with attention-deficit/hyperactivity disorder (ADHD). Poster presented at American Academy of Child and Adolescent Psychiatry, San Antonio, TX.
- Johnson J. K. Saylor K. Brittain S. T. Tulloch G. Liranso T. (2017, 10 23-28). A double-blind, placebo-controlled, dose-ranging study of extended-release viloxazine (SPN-812 ER) in children with ADHD. Abstract presented at American Academy of Child and Adolescent Psychiatry, Washington, DC.
- Shire US Inc. (2017). INTUNIV® (guanfacine) extended-release tablets, for oral use, prescribing information. Lexington, MA: Author.
Cited by
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Yu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., & Maletic, V. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s256586 · Cited by 96
Self-citationNasser, A., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Chowdhry, F., Busse, G. D., Cutler, A. J., Jones, N. J., Findling, R. L., et al. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.021 · Cited by 85
Self-citationViloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021) · CNS Drugs · doi:10.1007/s40263-021-00825-w · Cited by 55
“In a recent phase II trial in children aged 6–12 years with ADHD (n = 222), treatment-emergent AEs (TEAEs) were generally mild or moderate, with only three severe TEAEs reported (tearfulness, irritability, and decreased appetite) [68].”
BackgroundSelf-citationEmerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)
Pozzi, M., Bertella, S., Gatti, E., Peeters, G. G. A. M., Carnovale, C., Zambrano, S., & Nobile, M. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1820481 · Cited by 55
Metadata
- Authors
- Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H.
- Affiliations
- Supernus Pharmaceuticals (United States) (US)
- NeuroScience, Inc., Herndon, VA, USA
- Kennedy Krieger Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Nasser, Azmi
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2019-03-29
- Volume
- 24
- Issue
- 2
- Pages
- 348-358
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- PMC
- PMC6939319
- OpenAlex
- W2933452394
- Cited by
- 62
- References
- 24
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 10 · 2023: 7 · 2022: 13 · 2021: 15 · 2020: 7 · 2019: 1
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Attention Disorders (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Supernus Pharmaceuticals, Inc.
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- attention deficit hyperactivity disorder, children, ADHD-RS-IV, Clinical Global Impression Scale, suicidality, adverse events, sleepiness, drug efficacy, drug safety, norepinephrine reuptake inhibitors
- MeSH terms
- Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Delayed-Action Preparations, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Viloxazine, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD. https://app.cochat.ai/papers/10.1177/1087054719836159
- The paper
- Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020). A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD. Journal of Attention Disorders. https://doi.org/10.1177/1087054719836159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.